-- Safety update shows Phase 1 study unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy --
-- Company expects to reduce workforce reflective of narrowed preclinical development pipeline; continues to prudently advance programs while completing the assessment of its strategic alternatives --
PR Newswire
CAMBRIDGE, Mass., April 4, 2019